Navigation Links
IRIDEX Announces FDA 510(k) and CE Clearance of New Laser Delivery System for Fast, Non-invasive Treatment of Serious Retinal Diseases
Date:12/3/2012

MOUNTAIN VIEW, Calif., Dec. 3, 2012 /PRNewswire/ -- IRIDEX Corporation (NASDAQ: IRIX) today announced the FDA 510(k) and CE clearance of the TxCell Scanning Laser Delivery System.  The new product saves significant time in a variety of laser photocoagulation procedures in allowing physicians to deliver the laser in a multi-spot scanning mode, a more efficient method for these procedures than the traditional single spot mode.  

"Broadening market acceptance for medical technologies typically involves effective clinical results, ease of use for the physicians and more efficient use of time.  TxCell can deliver all three benefits and is an important step in accelerating the adoption of our proprietary MicroPulse technology as it applies to several clinical procedures," stated Will Moore, IRIDEX President and CEO. 

Giovanni Staurenghi, MD, Professor of Ophthalmology and Chairman of the Eye Clinic Ospedale Sacco at the University of Milan was the first to use the new system.  Prof. Staurenghi stated, "TxCell Scanning Laser Delivery System with the IQ 577 offers an intuitive and versatile way to deliver several advanced laser modalities."

The TxCell Scanning Laser Delivery System combined with an IRIDEX IQ 532 or IQ 577 laser enabled with MicroPulse is designed to provide the ophthalmologist a highly versatile system with three laser modalities – multi-spot scanning, single spot standard, and MicroPulse Laser Therapy. Initial shipments have commenced with orders from a number of different countries.

About MicroPulse Technology
MicroPulse is a Fovea-friendly tissue-sparing laser delivery therapy that works by electronically "chopping" the laser emission into trains of microsecond pulses. This enhances the physician's ability to more precisely control the laser effects on target tissues, offering the potential for ocular treatment with less collateral effects than conventional laser treatments. 

About IRIDEX
IRIDEX Corporation was founded in 1989 and is a worldwide leader in developing, manufacturing, and marketing innovative and versatile laser-based medical systems, delivery devices and consumable instrumentation for the ophthalmology market. We maintain a deep commitment to the success of our customers, with comprehensive technical, clinical, and service support programs. IRIDEX is dedicated to a standard of excellence, offering superior technology for superior results. IRIDEX products are sold in the United States through a direct sales force and internationally through a combination of a direct sales force and a network of approximately 70 independent distributors into over 100 countries. For further information, visit the IRIDEX website at http://www.iridex.com/.

Safe Harbor Statement
This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Act of 1934, as amended, relating to the effectiveness and market acceptance of the TxCell Scanning Laser Delivery System and MicroPulse laser therapy, and IRIDEX' marketing and sales efforts.  These statements are not guarantees of future performance and actual results may differ materially from those described in these forward-looking statements as a result of a number of factors.  Please see a detailed description of these and other risks contained in our Annual Report on Form 10-K for the fiscal year ended December 31, 2011, and our Quarterly Reports on Form 10-Q for the fiscal quarters ended March 31, 2012, June 30, 2012, and September 29, 2012, each of which was filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date and will not be updated.


'/>"/>
SOURCE IRIDEX Corporation
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. QUANTEL Medical Signs Global Licensing Agreement with IRIDEX
2. IRIDEX Announces Tender Offer to Purchase up to 487,500 Shares of its Common Stock
3. IRIDEX Reports 2012 Third Quarter Results
4. IRIDEX Announces Third Quarter 2012 Conference Call and Release Date
5. IRIDEX Appoints Chairman William M. Moore as Interim President & CEO
6. IRIDEX Reports 2012 Second Quarter Results
7. IRIDEX Announces Second Quarter 2012 Conference Call and Release Date
8. IRIDEX Reports 2012 First Quarter Results
9. IRIDEX Introduces Non-Invasive MicroPulseâ„¢ Therapy for Glaucoma
10. Hill-Rom Announces First Quarter 2013 Dividend
11. PDL BioPharma Announces Resignation of Chief Financial Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... 23, 2016 Any dentist who has made an ... current process. Many of them do not even offer this ... and high laboratory costs involved. And those who ARE able ... such a high cost that the majority of today,s patients ... Parsa Zadeh , founder of Dental Evolutions Inc. and ...
(Date:6/23/2016)... 23, 2016 Capricor Therapeutics, ... a biotechnology company focused on the discovery, development ... patient enrollment in its ongoing randomized HOPE-Duchenne clinical ... 50% of its 24-patient target. Capricor expects the ... quarter of 2016, and to report top line ...
(Date:6/23/2016)... and BOGOTA, Colombia , June 23, 2016  Astellas today announced the establishment of ... Farma Brasil as the company,s second affiliate in Latin America . ... ... Manager of Astellas Farma Colombia ... ...
Breaking Medicine Technology:
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article ... are unfamiliar with. The article goes on to state that individuals are now more ... these less common operations such as calf and cheek reduction. The Los Angeles area ...
(Date:6/24/2016)... ... June 24, 2016 , ... June 19, 2016 is World Sickle ... chronic pain and the benefits of holistic treatments, Serenity Recovery Center of ... Sickle Cell Disease. , Sickle Cell Disease (SCD) is a disorder of the red ...
(Date:6/24/2016)... ... 2016 , ... The Pulmonary Hypertension Association (PHA) learned during ... two significant new grants to support its work to advance research and patient ... recognizing patients, medical professionals and scientists for their work in fighting pulmonary hypertension ...
(Date:6/24/2016)... San Francisco, CA (PRWEB) , ... June 24, ... ... at CitiDent, is now offering micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has ... , self-ligating Damon brackets , AcceleDent, and accelerated osteogenic orthodontics. , ...
(Date:6/24/2016)... ... June 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain Relief Products, ... minimum wage raise to $12 an hour by 2020 and then adjusting it yearly to ... value of the minimum wage, assure the wage floor does not erode again, and make ...
Breaking Medicine News(10 mins):